{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T02:10:27Z","timestamp":1790647827468,"version":"4.1.0"},"reference-count":67,"publisher":"Impact Journals, LLC","issue":"51","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2019,9,3]]},"DOI":"10.18632\/oncotarget.26985","type":"journal-article","created":{"date-parts":[[2019,9,3]],"date-time":"2019-09-03T13:55:58Z","timestamp":1567518958000},"page":"5255-5266","source":"Crossref","is-referenced-by-count":22,"title":["Targeted drug combination therapy design based on driver genes"],"prefix":"10.18632","volume":"10","author":[{"given":"Lilian","family":"Zs\u00e1kai","sequence":"first","affiliation":[{"name":"Vichem Chemie Research Ltd., Budapest, Hungary"},{"name":"Department of Hematology and Stem Cell Transplantation, Central Hospital of Southern Pest National Institute of Hematology and Infectious Diseases, Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Sipos","sequence":"additional","affiliation":[{"name":"Vichem Chemie Research Ltd., Budapest, Hungary"},{"name":"Oncompass Medicine Hungary Ltd., Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judit","family":"Dobos","sequence":"additional","affiliation":[{"name":"Vichem Chemie Research Ltd., Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00e1niel","family":"Er\u0151s","sequence":"additional","affiliation":[{"name":"Vichem Chemie Research Ltd., Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Csaba","family":"Sz\u00e1ntai-Kis","sequence":"additional","affiliation":[{"name":"Vichem Chemie Research Ltd., Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e9ter","family":"B\u00e1nhegyi","sequence":"additional","affiliation":[{"name":"Vichem Chemie Research Ltd., Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e1nos","family":"Pat\u00f3","sequence":"additional","affiliation":[{"name":"Vichem Chemie Research Ltd., Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e1szl\u00f3","family":"\u0150rfi","sequence":"additional","affiliation":[{"name":"Vichem Chemie Research Ltd., Budapest, Hungary"},{"name":"Department of Pharmaceutical Chemistry, Semmelweis University, Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsolt","family":"Matula","sequence":"additional","affiliation":[{"name":"Department of Hematology and Stem Cell Transplantation, Central Hospital of Southern Pest National Institute of Hematology and Infectious Diseases, Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e1bor","family":"Mikala","sequence":"additional","affiliation":[{"name":"Department of Hematology and Stem Cell Transplantation, Central Hospital of Southern Pest National Institute of Hematology and Infectious Diseases, Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gy\u00f6rgy","family":"K\u00e9ri","sequence":"additional","affiliation":[{"name":"Vichem Chemie Research Ltd., Budapest, Hungary"},{"name":"MTA-SE Patho-Biochemistry Research Group, Department of Medical Chemistry, Semmelweis University, Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Istv\u00e1n","family":"Pet\u00e1k","sequence":"additional","affiliation":[{"name":"Oncompass Medicine Hungary Ltd., Budapest, Hungary"},{"name":"Department of Pharmacology, Semmelweis University, Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Istv\u00e1n","family":"V\u00e1lyi-Nagy","sequence":"additional","affiliation":[{"name":"Department of Hematology and Stem Cell Transplantation, Central Hospital of Southern Pest National Institute of Hematology and Infectious Diseases, Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2019,9,3]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1126\/science.1235122","article-title":"Cancer genome landscapes","volume":"339","author":"Kinzler","year":"2013","journal-title":"Science"},{"key":"2","doi-asserted-by":"publisher","first-page":"3538","DOI":"10.1038\/srep03538","article-title":"Identifying potential cancer driver genes by genomic data integration","volume":"3","author":"Jiang","year":"2013","journal-title":"Sci Rep"},{"key":"3","doi-asserted-by":"publisher","first-page":"4372","DOI":"10.1158\/0008-5472.CAN-12-3342","article-title":"The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology","volume":"73","author":"Doroshow","year":"2013","journal-title":"Cancer Res"},{"key":"4","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/nrd3135","article-title":"Integrating molecular diagnostics into anticancer drug discovery","volume":"9","author":"K\u00e9ri","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"5","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1136\/jclinpath-2014-202447","article-title":"Next-generation sequencing reveals frequent consistent genomic alterations in small cell undifferentiated lung cancer","volume":"67","author":"Elvin","year":"2014","journal-title":"J Clin Pathol"},{"key":"6","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Butler","year":"2013","journal-title":"Nature"},{"key":"7","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1073\/pnas.1421839112","article-title":"Only three driver gene mutations are required for the development of lung and colorectal cancers","volume":"112","author":"Vogelstein","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"key":"8","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nrd.2016.3","article-title":"Combination therapies in oncology","volume":"15","author":"Webster","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"9","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/bjc.2012.581","article-title":"Cancer heterogeneity: implications for targeted therapeutics","volume":"108","author":"Swanton","year":"2013","journal-title":"Br J Cancer"},{"key":"10","doi-asserted-by":"publisher","first-page":"e00747","DOI":"10.7554\/eLife.00747","article-title":"Evolutionary dynamics of cancer in response to targeted combination therapy","volume":"2","author":"Diaz","year":"2013","journal-title":"eLife"},{"key":"11","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1126\/science.1260825","article-title":"Cancer etiology","volume":"347","author":"Vogelstein","year":"2015","journal-title":"Variation in cancer risk among tissues can be explained by the number of stem cell divisions. Science"},{"key":"12","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/nature11219","article-title":"The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers","volume":"486","author":"Vogelstein","year":"2012","journal-title":"Nature"},{"key":"13","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1126\/science.1241328","article-title":"Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA","volume":"343","author":"Ohashi","year":"2014","journal-title":"Science"},{"key":"14","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/nature11249","article-title":"Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors","volume":"487","author":"Moffat","year":"2012","journal-title":"Nature"},{"key":"15","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/nm.3854","article-title":"Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M","volume":"21","author":"Cantarini","year":"2015","journal-title":"Nat Med"},{"key":"16","doi-asserted-by":"publisher","first-page":"3775","DOI":"10.1158\/1078-0432.CCR-13-2181","article-title":"Primary and acquired resistance of colorectal cancer cells to anti-EGFR antibodies converge on MEK\/ERK pathway activation and can be overcome by combined MEK\/EGFR inhibition","volume":"20","author":"Martinelli","year":"2014","journal-title":"Clin Cancer Res"},{"key":"17","first-page":"532","article-title":"Cancer: combination therapy for lung cancer","volume":"15","author":"Crunkhorn","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"18","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1038\/nchembio.117","article-title":"Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases","volume":"4","author":"Knight","year":"2008","journal-title":"Nat Chem Biol"},{"key":"19","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.4161\/15384047.2014.956634","article-title":"Combined inhibition of AXL, Lyn and p130Cas kinases block migration of triple negative breast cancer cells","volume":"15","author":"Torka","year":"2014","journal-title":"Cancer Biol Ther"},{"key":"20","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.neo.2014.03.009","article-title":"Activation of HER3 interferes with antitumor effects of Axl receptor tyrosine kinase inhibitors: suggestion of combination therapy","volume":"16","author":"Ullrich","year":"2014","journal-title":"Neoplasia"},{"key":"21","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1021\/ml4003309","article-title":"Discovery and biological evaluation of novel dual EGFR\/c-Met inhibitors","volume":"5","author":"K\u00e9ri","year":"2014","journal-title":"ACS Med Chem Lett"},{"key":"22","doi-asserted-by":"publisher","first-page":"10182","DOI":"10.1038\/srep10182","article-title":"Targets of drugs are generally, and targets of drugs having side effects are specifically good spreaders of human interactome perturbations","volume":"5","author":"Csermely","year":"2015","journal-title":"Sci Rep"},{"key":"23","doi-asserted-by":"publisher","first-page":"4104","DOI":"10.1158\/1078-0432.CCR-12-0055","article-title":"Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling","volume":"18","author":"DellaRocca","year":"2012","journal-title":"Clin Cancer Res"},{"key":"24","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/nature09837","article-title":"Initial genome sequencing and analysis of multiple myeloma","volume":"471","author":"Auclair","year":"2011","journal-title":"Nature"},{"key":"25","first-page":"11","article-title":"The Catalogue of Somatic Mutations in Cancer (COSMIC)","volume":"10","author":"Stratton","year":"2008","journal-title":"Curr Protoc Hum Genet"},{"key":"26","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/nm1087","article-title":"Cancer genes and the pathways they control","volume":"10","author":"Kinzler","year":"2004","journal-title":"Nat Med"},{"key":"27","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1089\/adt.2005.3.543","article-title":"Drug discovery in the kinase inhibitory field using the Nested Chemical Library technology","volume":"3","author":"Greff","year":"2005","journal-title":"Assay Drug Dev Technol"},{"key":"28","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"Talalay","year":"1984","journal-title":"Adv Enzyme Regul"},{"key":"29","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the Chou-Talalay method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res"},{"key":"30","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1182\/blood-2014-05-578732","article-title":"The Tao of myeloma","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"31","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/nrc3257","article-title":"The genetic architecture of multiple myeloma","volume":"12","author":"Davies","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"32","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1182\/blood-2012-01-405977","article-title":"Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides","volume":"120","author":"Bergsagel","year":"2012","journal-title":"Blood"},{"key":"33","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1158\/1078-0432.CCR-11-2488","article-title":"Randomized phase II trial of sorafenib with temsirolimus or tipifarnib in untreated metastatic melanoma (S0438)","volume":"18","author":"Sondak","year":"2012","journal-title":"Clin Cancer Res"},{"key":"34","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.leukres.2010.12.010","article-title":"Cyclin-dependent kinase inhibitor, P276-00 induces apoptosis in multiple myeloma cells by inhibition of Cdk9-T1 and RNA polymerase II-dependent transcription","volume":"35","author":"Joshi","year":"2011","journal-title":"Leuk Res"},{"key":"35","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1158\/1535-7163.MCT-10-0324","article-title":"Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor","volume":"9","author":"Fischmann","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"36","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1101\/gad.11.5.663","article-title":"Cooperating oncogenes converge to regulate cyclin\/cdk complexes","volume":"11","author":"Land","year":"1997","journal-title":"Genes Dev"},{"key":"37","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1021\/jm901453q","article-title":"Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer","volume":"53","author":"Qian","year":"2010","journal-title":"J Med Chem"},{"key":"38","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.bbcan.2014.07.010","article-title":"Histone deacetylase 2 controls p53 and is a critical factor in tumorigenesis","volume":"1846","author":"Kr\u00e4mer","year":"2014","journal-title":"Biochim Biophys Acta"},{"key":"39","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1158\/1535-7163.MCT-10-0034","article-title":"Evaluation of selective gamma-secretase inhibitor PF-03084014 for its antitumor efficacy and gastrointestinal safety to guide optimal clinical trial design","volume":"9","author":"Smeal","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"40","doi-asserted-by":"publisher","first-page":"6092","DOI":"10.1038\/onc.2015.55","article-title":"Anti-androgen flutamide suppresses hepatocellular carcinoma cell proliferation via the aryl hydrocarbon receptor mediated induction of transforming growth factor-\u03b21","volume":"34","author":"Kolluri","year":"2015","journal-title":"Oncogene"},{"key":"41","doi-asserted-by":"publisher","first-page":"3413","DOI":"10.1158\/0008-5472.CAN-07-1919","article-title":"Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax)","volume":"68","author":"Andreeff","year":"2008","journal-title":"Cancer Res"},{"key":"42","doi-asserted-by":"publisher","first-page":"3421","DOI":"10.1158\/0008-5472.CAN-07-5836","article-title":"ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor","volume":"68","author":"Xiao","year":"2008","journal-title":"Cancer Res"},{"key":"43","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/1476-4598-13-98","article-title":"The Bcl-2\/xL inhibitor ABT-263 increases the stability of Mcl-1 mRNA and protein in hepatocellular carcinoma cells","volume":"13","author":"He","year":"2014","journal-title":"Mol Cancer"},{"key":"44","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1097\/01.cad.0000224459.13651.fd","article-title":"Role of nerve growth factor and its receptors in non-nervous cancer growth: efficacy of a tyrosine kinase inhibitor (AG879) and neutralizing antibodies antityrosine kinase receptor A and antinerve growth factor: anandstudy","volume":"17","author":"Sanna","year":"2006","journal-title":"Anticancer Drugs"},{"key":"45","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/bjc.2012.582","article-title":"Dp44mT targets the AKT, TGF-\u03b2 and ERK pathways via the metastasis suppressor NDRG1 in normal prostate epithelial cells and prostate cancer cells","volume":"108","author":"Richardson","year":"2013","journal-title":"Br J Cancer"},{"key":"46","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1126\/science.1234769","article-title":"Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation","volume":"340","author":"Artin","year":"2013","journal-title":"Science"},{"key":"47","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1093\/oxfordjournals.jbchem.a021280","article-title":"Differential inhibition of calpain and proteasome activities by peptidyl aldehydes of di-leucine and tri-leucine","volume":"119","author":"Kawashima","year":"1996","journal-title":"J Biochem"},{"key":"48","doi-asserted-by":"publisher","first-page":"3202","DOI":"10.4161\/15384101.2014.950132","article-title":"Proteasome inhibitors suppress the protein expression of mutant p53","volume":"13","author":"Gartel","year":"2014","journal-title":"Cell Cycle"},{"key":"49","doi-asserted-by":"publisher","first-page":"3281","DOI":"10.1182\/blood-2007-01-065888","article-title":"Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma","volume":"110","author":"Orlowski","year":"2007","journal-title":"Blood"},{"key":"50","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1021\/jm201112g","article-title":"Discovery of kinase spectrum selective macrocycle (16E)-14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (SB1317\/TG02), a potent inhibitor of cyclin dependent kinases (CDKs), Janus kinase 2 (JAK2), and fms-like tyrosine kinase-3 (FLT3) for the treatment of cancer","volume":"55","author":"Jayaraman","year":"2012","journal-title":"J Med Chem"},{"key":"51","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3892\/ijo.2011.1015","article-title":"Antitumor activities of JTP-74057 (GSK1120212), a novel MEK1\/2 inhibitor, on colorectal cancer cell linesand","volume":"39","author":"Sakai","year":"2011","journal-title":"Int J Oncol"},{"key":"52","doi-asserted-by":"publisher","first-page":"4758","DOI":"10.1158\/0008-5472.can-10-2527","article-title":"VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer","volume":"71","author":"McDonald","year":"2011","journal-title":"Cancer Res"},{"key":"53","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/nature12796","article-title":"K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions","volume":"503","author":"Shokat","year":"2013","journal-title":"Nature"},{"key":"54","doi-asserted-by":"publisher","first-page":"7653","DOI":"10.1016\/j.bmcl.2012.10.007","article-title":"SAR andevaluation of 4-aryl-2-aminoalkylpyrimidines as potent and selective Janus kinase 2 (JAK2) inhibitors","volume":"22","author":"Huynh","year":"2012","journal-title":"Bioorg Med Chem Lett"},{"key":"55","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1021\/ml900028r","article-title":"Discovery of GSK2126458, a highly potent inhibitor of PI3K and the mammalian target of rapamycin","volume":"1","author":"Van Aller","year":"2010","journal-title":"ACS Med Chem Lett"},{"key":"56","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1158\/1535-7163.MCT-13-0709","article-title":"Characterization of the activity of the PI3K\/mTOR inhibitor XL765 (SAR245409) in tumor models with diverse genetic alterations affecting the PI3K pathway","volume":"13","author":"Abulafia","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"57","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1158\/1535-7163.MCT-09-1012","article-title":"MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugsand","volume":"9","author":"Kotani","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"58","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1158\/0008-5472.CAN-10-2889","article-title":"eEF-2 kinase dictates cross-talk between autophagy and apoptosis induced by Akt Inhibition, thereby modulating cytotoxicity of novel Akt inhibitor MK-2206","volume":"71","author":"Yang","year":"2011","journal-title":"Cancer Res"},{"key":"59","doi-asserted-by":"publisher","first-page":"5511","DOI":"10.1038\/onc.2008.246","article-title":"Drug discovery approaches targeting the PI3K\/Akt pathway in cancer","volume":"27","author":"Sellers","year":"2008","journal-title":"Oncogene"},{"key":"60","doi-asserted-by":"publisher","first-page":"4961","DOI":"10.1038\/ncomms5961","article-title":"Activation of diverse signalling pathways by oncogenic PIK3CA mutations","volume":"5","author":"Neiswinger","year":"2014","journal-title":"Nat Commun"},{"key":"61","doi-asserted-by":"publisher","first-page":"3158","DOI":"10.1158\/1535-7163.MCT-07-0444","article-title":"PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer","volume":"6","author":"Zugnoni","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"62","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.cub.2006.12.037","article-title":"BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth","volume":"17","author":"Rettig","year":"2007","journal-title":"Curr Biol"},{"key":"63","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.mrrev.2014.02.005","article-title":"Plk1-targeted therapies in TP53- or RAS-mutated cancer","volume":"761","author":"Erikson","year":"2014","journal-title":"Mutat Res Rev Mutat Res"},{"key":"64","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/nchembio.137","article-title":"Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer","volume":"5","author":"Lum","year":"2009","journal-title":"Nat Chem Biol"},{"key":"65","doi-asserted-by":"publisher","first-page":"359","DOI":"10.2174\/138620712800194468","article-title":"A high throughput scintillation proximity imaging assay for protein methyltransferases","volume":"15","author":"Djaballah","year":"2012","journal-title":"Comb Chem High Throughput Screen"},{"key":"66","doi-asserted-by":"publisher","first-page":"6424","DOI":"10.1158\/0008-5472.CAN-04-1906","article-title":"Nrf2 is essential for the chemopreventive efficacy of oltipraz against urinary bladder carcinogenesis","volume":"64","author":"Yamamoto","year":"2004","journal-title":"Cancer Res"},{"key":"67","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2012.15","article-title":"Latest advances and current challenges in the treatment of multiple myeloma","volume":"135","author":"Anderson","year":"2012","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.26985","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,6]],"date-time":"2020-06-06T14:43:50Z","timestamp":1591454630000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.26985"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,3]]},"references-count":67,"journal-issue":{"issue":"51","published-print":{"date-parts":[[2019,9,3]]}},"alternative-id":["26985","31523388"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.26985","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,3]]}}}